Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817528 · ClinicalTrials.gov registry record · Phase 2
ITI-007 (Lumateperone Tosylate) for Schizophrenia
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03817528 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 4 participants.
The verdict
NCT03817528, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to offer open label ITI-007 treatment to patients who poorly respond or poorly tolerate approved medications.
Interventions
- DRUG ITI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2020-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817528
The ClinicalTrials.gov registry entry for NCT03817528 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ITI-007 is the first listed.
NCT03817528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03817528 about?
NCT03817528 is a clinical study titled "ITI-007 (Lumateperone Tosylate) for Schizophrenia". The purpose of this study is to offer open label ITI-007 treatment to patients who poorly respond or poorly tolerate approved medications.
What is the current status of trial NCT03817528?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-03-01. Estimated completion is 2020-09-23.
What interventions are being tested in trial NCT03817528?
The interventions under investigation include: ITI-007 (DRUG).
Who is sponsoring clinical trial NCT03817528?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.